Welcome to cwg.live, updated around-the-clock by Capital Weather Gang meteorologists. Happening now: The worst of storms have ...

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...

An information technology specialist for the Defense Intelligence Agency was charged Thursday with attempting to transmit classified information to a representative of a foreign ...

Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...

DelveInsight's B-cell Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its ...

Indigenous leaders across the Gulf say it’s imperative that Alaska legislators pass reforms to the state law that they blame for the mess: a landmark 1973 statute that effectively prevents many ...

Finally, a line has been drawn under the worst period in the history of our football club. After eight years of shite, that ...

On the 120th and last day of Alaska’s annual legislative session, the state House passed a bill that would curb high interest ...

The Democrats neglected their voter base in 2024 and failed to respond to Trump’s campaign with anything beyond the ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

Plenge currently works at PhRMA Foundation, as Director and Bristol Myers Squibb Co., as Chief Research Officer, Head-Research & EVP from 2019. Dr. Plenge also formerly worked at Translate Bio, Inc., ...